Near-term catalysts 1Q-2Q11 -Top line data from Lymphoseek NEO3-09 Phase III study in Feb. -Presentation of detailed NEO3-09 Phase III dataset. -Submission of Lymphoseek NDA -FDA pre-IND Meeting for RIGScan CR49 -New IND for RIGScan to reinitiate clinical development -Clarification of full RIGS development & registration plan with FDA and EMA -Possible listing on major exchange
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.